

Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection

Smith-Vaughan, Heidi C.; Cheng, Allen C.; Tabrizi, Sepehr N.; Wurzel, Danielle F.; Beissbarth, Jemima; Leach, Amanda J.; Morris, Peter S.; Binks, Michael J.; Torzillo, Paul J.; Chang, Anne B.; Marsh, Robyn L.

Published in:
Pediatric Investigation

DOI:
[10.1002/ped4.12262](https://doi.org/10.1002/ped4.12262)

Published: 01/06/2021

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

Smith-Vaughan, H. C., Cheng, A. C., Tabrizi, S. N., Wurzel, D. F., Beissbarth, J., Leach, A. J., Morris, P. S., Binks, M. J., Torzillo, P. J., Chang, A. B., & Marsh, R. L. (2021). Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection. *Pediatric Investigation*, 5(2), 136-139. <https://doi.org/10.1002/ped4.12262>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

BRIEF REPORT

WILEY

Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection

Heidi C Smith-Vaughan^{1,2} | Allen C Cheng³ | Sepehr N. Tabrizi^{4,5} | Danielle F Wurzel⁴ | Jemima Beissbarth¹ | Amanda J Leach¹ | Peter S Morris^{1,6} | Michael J Binks¹ | Paul J Torzillo⁷ | Anne B Chang^{1,8} | Robyn L Marsh¹

¹Menzies School of Health Research, Charles Darwin University, Darwin, Australia

²School of Medicine, Griffith University, Gold Coast, Australia

³Monash University, Melbourne, Australia

⁴Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Australia

⁵Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia

⁶Royal Darwin Hospital, Darwin, Australia

⁷Royal Prince Alfred Hospital, Sydney, Australia

⁸Dept of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane, Australia

Correspondence

Heidi Smith-Vaughan, Menzies School of Health Research, Building 58, Royal Darwin Hospital, Rocklands Drive, Darwin, Northern Territory 0810, Australia

Email: Heidi.Smith-Vaughan@menzies.edu.au

Funding source

This work was supported by the Australian National Health and Medical Research Council (NHMRC, GNT1023781); HSV was supported by the NHMRC Centre for Research Excellence for Lung Health in Aboriginal and Torres Strait Islander children (GNT1079557); ABC is funded by a NHMRC Practitioner Fellowship (1154302); ACC was supported by a Career Development Fellowship (1068732).

Received: 2 October, 2020

Accepted: 2 December, 2020

ABSTRACT

Maternal urogenital human papillomavirus (HPV) infection may place neonates at risk of HPV acquisition and subsequently lower respiratory infections as HPV can influence development of immunity. The respiratory HPV prevalence is not known in remote-dwelling Aboriginal infants, who are at high risk of respiratory infection and where the population prevalence of urogenital HPV in women is high. These data are necessary to inform HPV vaccination regimens. A retrospective analysis using PCR specific for HPV was performed on 64 stored nasopharyngeal swabs from remote-dwelling Aboriginal infants < 6 months of age, with and without hospitalised pneumonia. HPV DNA was not detected in any specimen. Despite the negative result, we cannot exclude a role for HPV in respiratory infections affecting infants in this population; however, our data do not support HPV as an important contributor to acute respiratory infection in remote-dwelling Aboriginal children.

KEYWORDS

Human papillomavirus, Nasopharyngeal swabs, Infants

DOI: 10.1002/ped4.12262

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

©2021 Chinese Medical Association. *Pediatric Investigation* published by John Wiley & Sons Australia, Ltd on behalf of Futang Research Center of Pediatric Development.

INTRODUCTION

Human papillomavirus (HPV) disease has a wide range of clinical manifestations. HPV genotypes associated with oncology diseases are involved in the development of genitourinary and oropharyngeal cancers, while other genotypes can cause genital warts and serious respiratory disorders in both adults and children.¹ Respiratory papillomatosis is a rare condition, but is the most common benign neoplasm of the larynx among children.² This condition is primarily caused by types HPV-6 and HPV-11² which are targeted by the quadrivalent and nonavalent HPV vaccines (Gardasil[®] and Gardasil9[®]).

In infants, the most commonly known manifestation of HPV is respiratory papillomatosis where stridor is often the presenting symptom. However, HPV infection is also associated with impaired humoral and innate immune responses that predispose the child to increased risk of infection.³ Children may thus also present with recurrent pneumonia, bronchiectasis, and declining pulmonary status.² In Australia between 2000 and 2013, the estimated prevalence of respiratory papillomatosis was 0.81 per 100 000 among children aged < 15 years, peaking at age 5 to 9 years (1.1 per 100 000),⁴ and is expected to decline with broader HPV vaccine coverage.

Children may acquire HPV *in utero*, perinatally, or subsequently through horizontal transmission via saliva or other contacts.⁵ Ten international studies examining HPV DNA in nasopharyngeal aspirates taken from neonates after delivery, reported prevalences varying from 1.5% to 37%.⁵ In addition, seven studies that examined HPV DNA in buccal swabs collected from infants aged 1–4 days reported prevalence of 0.9% to 56%.⁵ Subsequently, HPV DNA can persist in some children; the Finnish Family Study found that HPV DNA persisted for at least 36 months in 10% of infants positive at delivery for high-risk HPV genotypes (12 HPV types examined of > 206 identified types).⁶

Currently, there are no known data on HPV DNA prevalence in respiratory specimens in Australian Aboriginal children. This is despite a high prevalence of urogenital HPV infection in Aboriginal women in northern Australia (42% [95% CI, 37%–48%] in one community-based study)⁷ prior to vaccine introduction and known vertical transmission of the virus.⁵ Further, Australian children living in remote Northern Territory communities experience high rates of acute and chronic lower respiratory infection (ALRI), including pneumonia, with one fifth hospitalised with an ALRI in the first year of life,⁸ and 1 in 68 diagnosed with bronchiectasis.⁹ It is unknown whether airway infection with HPV contributes to the development of acute and/or chronic lower respiratory tract infections in Aboriginal children in remote communities. Should HPV in the upper airways prove

to be prevalent in children at risk of lower respiratory infection, expansion of HPV vaccination regimens to at-risk infants may be warranted.

Our aim was to determine the prevalence of HPV DNA in nasopharyngeal swabs (NPS) from infants up to six months of age with and without pneumonia. We hypothesised that HPV DNA would be detected in NPS specimens from Aboriginal infants from remote communities, with higher positivity in those who had pneumonia.

METHODS

Ethical approval

Retrospective analysis of NPS was approved by the Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research (2011-1668) and conforms to the provisions of the Declaration of Helsinki. The NPS were sourced from children with and without pneumonia enrolled in three studies (1996–2004)¹⁰⁻¹² with written informed consent for further laboratory analyses. Patient anonymity was preserved.

NPS testing

NPS specimens collected from 40 Aboriginal children from remote Northern Territory communities with no diagnosis of any ALRI and aged 3–25 weeks, and from 24 Aboriginal children hospitalised with pneumonia and aged 1 to 23 weeks (Table 1) were tested in 2013. Where longitudinal specimens were taken from an individual infant, only the first NPS was tested. These NPS represented all eligible specimens in the three studies where there was written informed consent for further laboratory analyses. The NPS had been collected into 1 mL skim milk tryptone glucose glycerol broth and stored at –80 °C. HPV DNA was previously shown to be detectable in vaginal swabs stored in media at –20 °C for at least 12 years.¹³ An aliquot of 200 µL of the NPS was extracted by the automated MagNA Pure 96 isolation and purification system (Roche Molecular Systems) using DNA and the Viral NA Small Volume kit. Each extracted sample was assessed for: i) Sample adequacy using a quantitative PCR for a 260-bp fragment of the human beta-globin gene¹⁴; and ii) HPV DNA using L1 consensus primers PGMY09/PGMY11^{15,16} combined with PCR-ELISA detection (with established sensitivity of 10 copies per reaction for the mucosal HPV genotypes).¹⁷

RESULTS

All NPS were positive for human beta-globin with an average of 2.49×10^3 and 2.24×10^3 copies per reaction detected for samples collected from children with and without pneumonia ($P = 0.366$). However, all (64/64) NPS were negative for HPV DNA (one-sided 97.5% CI, 0.94–1.0).

TABLE 1 Description of original studies

Study description	Years	Number of specimens	Median age (range), weeks	% HPV DNA positive
Children without pneumonia				
Placebo-controlled RCT of long-term amoxicillin (up to 6m) for treatment of OME in 3 communities. ¹⁰ Total enrolled; <i>n</i> = 103	1996–2001	40	7.64 (1.00–23.42)	0
Longitudinal carriage study of infants receiving PCV7 and 23PPV in 3 communities. ¹¹ Total enrolled; <i>n</i> = 148	2001–2004			
Children with pneumonia				
RCT of zinc and vitamin A supplementation in pneumonia. ¹² Total enrolled; <i>n</i> = 187	2001–2002	24	15.17 (2.99–25.35)	0

RCT, randomized controlled trial; OME, otitis media with effusion; PCV7, 7-valent pneumococcal conjugate vaccine; 23PPV, 23-valent pneumococcal polysaccharide vaccine; NPS, nasopharyngeal swab; m, months.

DISCUSSION

In this study we did not detect HPV DNA in NPS from a cohort of 64 Aboriginal infants up to six months of age with and without pneumonia. This absence of HPV is unlikely to be due to swab storage or inadequate sampling, as we successfully detected DNA from other virus species in these specimens,¹⁸ and human beta-globin gene levels indicated sufficient mucosal sampling.

The absence of HPV DNA needs to be considered in relation to the study design. This was a retrospective analysis of archived specimens collected for studies that were not designed to assess the prevalence of HPV.^{10–12} Therefore, the NPS under analysis varied in child age (between 1 and 25 weeks), and we did not know the HPV status of the mother and/or the primary carer. Furthermore, the cohort of 64 infants was small for this type of study but suggests a prevalence of <1.6% (ie. 1 in 64). The eligible sample number also represented a small proportion (13%–16%) of the original study enrolments and the annual Aboriginal birth cohort in the Northern Territory (approximately 1550). Given these limitations, we cannot exclude a role for HPV in respiratory infections (or infections at other body sites) affecting infants; however, our data do not support HPV as an important contributor to acute respiratory infection in the population tested.

Our study was performed on NPS collected during 1996–2004 prior to introduction of HPV vaccines. Prevalence data from well women's health checks for Aboriginal women in northern Australia in 1999 found HPV infection in 42% in 1090 women of all ages (and up to 62% in 16–20 year olds).⁷ Since introduction of HPV vaccination (Gardasil®) in Australia in 2007, there has been a marked reduction in clinic presentations for genital warts by Aboriginal and Torres Strait Islander Australians aged 21–30 years,¹⁹ but not in older age groups. Surveillance studies continue to monitor new cases of HPV disease and associated types; however, HPV-related disease remains a concern as does its role in humoral and innate immune

impairment.³ The question of whether HPV plays a role in the very high rates of respiratory infection with immune impairment²⁰ in Aboriginal infants remains incompletely addressed; however, our results suggest that vertical HPV transmission is an unlikely contributor. Whilst these data do not demonstrate a need for further research on prevalence of HPV in remote-dwelling Aboriginal infants, the broader implications of HPV vaccination strategies in groups with high disease rates remain important.

ACKNOWLEDGMENTS

We wish to thank the families who participated in these studies. We thank Victor Oguoma for assistance with statistical analysis.

CONFLICT OF INTEREST

None.

REFERENCES

- Maver PJ, Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. *Vaccine*. 2018;36:5416–5423.
- Derkey CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. *Laryngoscope*. 2008;118:1236–1247.
- Wu X, Wang G, Chen X, Zhang J, Zhao J, Wang J, et al. Impaired T Cell-dependent humoral immune response associated with Juvenile-onset recurrent respiratory papillomatosis progression. *Sci Rep*. 2016;6:36378.
- Novakovic D, Cheng AT, Baguley K, Walker P, Harrison H, Soma M, et al. Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates. *Laryngoscope*. 2016;126:2827–2832.
- Syrjänen S. Current concepts on human papillomavirus infections in children. *APMIS*. 2010;118:494–509.
- Rintala MA, Grénman SE, Järvenkylä ME, Syrjänen KJ, Syrjänen SM. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. *Clin Infect Dis*. 2005;41:1728–1733.
- Bowden FJ, Paterson BA, Mein J, Savage J, Fairley CK, Garland SM, et al. Estimating the prevalence of

- Trichomonas vaginalis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and human papillomavirus infection in Indigenous women in northern Australia. *Sex Transm Infect.* 1999;75:431-434.
8. O'Grady KA, Torzillo PJ, Chang AB. Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. *Med J Aust.* 2010;192:586-590.
 9. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non-CF bronchiectasis: clinical and HRCT evaluation. *Pediatr Pulmonol.* 2003;35:477-483.
 10. Leach AJ, Morris PS, Mathews JD. Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwIP) in a high-risk population: a randomized controlled trial. *BMC Pediatr.* 2008;8:23.
 11. Mackenzie GA, Carapetis JR, Leach AJ, Morris PS. Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination. *BMC Pediatr.* 2009;9:14.
 12. Chang AB, Torzillo PJ, Boyce NC, White AV, Stewart PM, Wheaton GR, et al. Zinc and vitamin A supplementation in Indigenous Australian children hospitalised with lower respiratory tract infection: a randomised controlled trial. *Med J Aust.* 2006;184:107-112.
 13. Herrera-Ortiz A, Conde-Glez CJ, Olamendi-Portugal ML, Garcia-Cisneros S, Plett-Torres T, Sánchez-Alemán MA. College women, HPV genotyping and sexual behavior before HPV vaccination: Results from samples stored for a long time. *J Infect Public Health.* 2018;11:286-289.
 14. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science.* 1988;239:487-491.
 15. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. *Cancer Cells.* 1989;7:209-214.
 16. Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. *J Natl Cancer Inst.* 1990;82:1477-1484.
 17. Layton-Henry J, Scurry J, Planner R, Allen D, Sykes P, Garland S, et al. Cervical adenoid basal carcinoma, five cases and literature review. *Int J Gynaecol Cancer.* 1996;6:193-199.
 18. Chang AB, Smith-Vaughan H, Sloots TP, Valery PC, Whiley D, Beissbarth J, et al. Upper airway viruses and bacteria detection in clinical pneumonia in a population with high nasal colonisation do not relate to clinical signs. *Pneumonia (Nathan).* 2015;6:48-56.
 19. Ali H, McManus H, O'Connor CC, Callander D, Kong M, Graham S, et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. *Med J Aust.* 2017;206:204-209.
 20. Pizzutto SJ, Yerkovich ST, Upham JW, Hales BJ, Thomas WR, Chang AB. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma *in vitro* in response to non-typeable *Haemophilus influenzae*. *PLoS One.* 2014;9:e104236.

How to cite this article: Smith-Vaughan HC, Cheng AC, Tabrizi SN, Wurzel DF, Beissbarth J, Leach AJ, et al. Absence of human papillomavirus in nasopharyngeal swabs from infants in a population at high risk of human papillomavirus infection. *Pediatr Investig.* 2021;5:136-139. <https://doi.org/10.1002/ped4.12262>